--- title: Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma nct_id: NCT00003718 overall_status: UNKNOWN phase: PHASE2 sponsor: Herbert Irving Comprehensive Cancer Center study_type: INTERVENTIONAL primary_condition: Endometrial Cancer countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00003718.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00003718" ct_last_update_post_date: 2014-01-06 last_seen_at: "2026-05-12T06:53:05.485Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma **Official Title:** Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas **NCT ID:** [NCT00003718](https://clinicaltrials.gov/study/NCT00003718) ## Key Facts - **Status:** UNKNOWN - **Phase:** PHASE2 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 25 - **Lead Sponsor:** Herbert Irving Comprehensive Cancer Center - **Conditions:** Endometrial Cancer, Ovarian Cancer, Sarcoma - **Start Date:** 1998-09 - **CT.gov Last Update:** 2014-01-06 ## Brief Summary RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced soft tissue sarcoma. ## Detailed Description OBJECTIVES: I. Determine the efficacy, as measured by the response rate, of temozolomide in patients with unresectable, stage IV, or recurrent soft tissue sarcoma who have failed no more than 2 prior treatment regimens. II. Determine the clinical and laboratory toxicities, as well as patient tolerance, of this regimen in this patient population. OUTLINE: Patients are stratified according to ECOG performance status (0-1 vs 2), prior surgery (yes vs no), prior radiotherapy (yes vs no), and prior chemotherapy regimens (0 vs 1 vs 2). Patients receive oral temozolomide every 12 hours for 5 days. Courses repeat every 4 weeks for at least 18 months in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 18 months, every 6 months for the next 18 months, and then annually thereafter until death. PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` DISEASE CHARACTERISTICS: Histologically, cytologically, or clinically confirmed unresectable, stage IV, or recurrent soft tissue sarcoma No Ewing's sarcoma, Kaposi's sarcoma, bone sarcomas, mesotheliomas, or primitive neuroectodermal tumors Bidimensionally measurable disease by x-ray, CT scan or MRI, or physical examination No CNS metastases No more than 2 prior chemotherapy regimens for advanced, recurrent, or metastatic disease PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Greater than 12 weeks Hematopoietic: Platelet count at least 100,000/mm3 Hemoglobin greater than 10.0 g/dL WBC at least 3,500/mm3 OR Absolute neutrophil count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT/SGPT no greater than 1.5 times ULN Alkaline phosphatase less than 2 times ULN Renal: Calcium less than ULN Creatinine or BUN less than 1.5 times ULN OR Creatinine clearance greater than 60 mL/min Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or fully excised and/or treated stage I cancer currently in complete remission No nonmalignant systemic disease rendering patient a poor medical risk No acute infection requiring IV antibiotics HIV negative No AIDS-related illness No frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction) PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic response modifier treatment allowed At least 4 weeks since prior immunotherapy At least 4 weeks since prior biologic therapy No concurrent epoetin alfa Chemotherapy: See Disease Characteristics Prior dacarbazine allowed At least 4 weeks since prior chemotherapy No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy for malignancy Radiotherapy: At least 3 weeks since prior radiotherapy and recovered No prior radiotherapy to areas of measurable disease unless there is clear progression or there is measurable disease outside the area of prior radiation No concurrent radiotherapy Surgery: At least 4 weeks since prior surgery and recovered Other: No other concurrent investigational drugs ``` ## Interventions - **temozolomide** (DRUG) ## Locations (1) - Herbert Irving Comprehensive Cancer Center, New York, New York, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.herbert irving comprehensive cancer center|new york|new york|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT00003718.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT00003718* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*